Effectiveness of omega-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  He, Xi Xi ^a   Wu, Xiao Li ^a   Chen, Ren Pin ^a   Chen, Chao ^a   Liu, Xiao Gang ^b   Wu, Bin Jiao ^c   Huang, Zhi Ming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b Ningxia Eye Hospital   (China)

^c China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER INJURY; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SUPPLEMENTATION; SYSTEMATIC REVIEW; TREATMENT DURATION; BLOOD; DIET RESTRICTION; ENZYMOLOGY; META ANALYSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES;

BLOOD GLUCOSE; FASTING; FATTY ACIDS, OMEGA-3; HUMANS; LIPIDS; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84990988117     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162368     Document Type: Article

References (56)

1. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016; 17 (6):510-9 doi: 10.1111/obr.12407 PMID: 27020692
2. Karnikowski M, Cordova C, Oliveira RJ, Karnikowski MG, Nobrega Ode T. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and older adults. Sao Paulo Med J. 2007; 125 (6):333-7. doi: 10.1590/s1516-31802007000600006 PMID: 18317603
3. Kumar R, Prakash S, Chhabra S, Singla V, Madan K, Gupta SD, et al. Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res. 2012; 136(2):229-36. PMID: 22960889
4. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci. 2000; 79(7):961-70. doi: 10.1093/ps/79.7.961 PMID: 10901194
5. Simopoulos AP. Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet. 2011; 102:10-21. doi: 10.1159/000327785 PMID: 21865815
6. Ristic V, Ristic G. [Role and importance of dietary polyunsaturated fatty acids in the prevention and therapy of atherosclerosis]. Med Pregl. 2003; 56(1-2):50-3. PMID: 12793187
7. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clinical science (London, England: 1979). 2004; 106(6):635-43. doi: 10.1042/ CS20030326 PMID: 14720121
8. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. Contemp Clin Trials. 2014; 37(2):301-11. doi: 10.1016/j.cct.2014.02.002 PMID: 24556343
9. Janczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 2013; 13:85. doi: 10.1186/1471-2431-13-85 PMID: 23702094
10. Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015; 49(2):137-44. doi: 10.1097/MCG. 0000000000000099 PMID: 24583757
11. Nogueira M.A. AVAF, Stefano J.T., Rodrigues L., Carrilho F.J., Waitzberg D., Oliveira C.P. Effects of omega-3 polyunsaturated fatty acids (PUFA) from fish and flaxseed oils on nonalcoholic steatohepatitis (NASH). Journal of Hepatology. 2013; 58 SUPPL. 1 (S544-)
12. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014; 147(2):377-84.e1. doi: 10.1053/j.gastro.2014.04.046 PMID: 24818764
13. Nogueira MA, Oliveira CP, Ferreira Alves VA, Stefano JT, Rodrigues LS, Torrinhas RS, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2015. doi: 10.1016/j.clnu.2015.05.001 PMID: 26047766
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA Statement. Open Med. 2009; 3(3):e123-30. doi: 10.7326/0003-4819-151-4-200908180-00135 PMID: 21603045
15. Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr. 2010; 61(8):792-802. doi: 10.3109/09637486.2010. 487480 PMID: 20465434
16. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008; 40(3):194-9. doi: 10.1016/j.dld.2007.10.003 PMID: 18054848
17. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008; 14 (41):6395-400. doi: 10.3748/wjg.14.6395 PMID: 19009658
18. Chen R GQ, Zhu WJ, Xie Q, Wang H, Cai W. Therapeutic efficacy of (omega)-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease. World Chin J Digestol. 2008; 16:2002-6. doi: 10.11569/wcjd.v16.i18.2002
19. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome∗ study. Hepatology. 2014; 60(4):1211-21. doi: 10.1002/hep.27289 PMID: 25043514
20. Li YH, Yang LH, Sha KH, Liu TG, Zhang LG, Liu XX. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol. 2015; 21(22):7008-13. doi: 10.3748/ wjg.v21.i22.7008 PMID: 26078579
21. Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015; 62(1):190-7. doi: 10.1016/j.jhep.2014.08.036 PMID: 25195547
22. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012; 56 (4):944-51. doi: 10.1016/j.jhep.2011.08.018 PMID: 22023985
23. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010; 52(1):79-104. doi: 10.1002/hep.23623 PMID: 20578268
24. Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013; 33(1):16-23. doi: 10.1111/j.1478-3231.2012.02807.x PMID: 22507181
25. Razny U, Kiec-Wilk B, Polus A, Goralska J, Malczewska-Malec M, Wnek D, et al. Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: A randomized placebo controlled trial. BBA Clin. 2015; 4:7-13 doi: 10.1016/j.bbacli.2015.05.001 PMID: 26925376
26. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005; 42(5):987-1000. doi: 10.1002/hep.20920 PMID: 16250043
27. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis. 2003; 35(3):172-8. doi: 10.1016/s1590-8658(03)00025-2 PMID: 12779071
28. Wang XC, Zhan XR, Li XY, Yu JJ, Liu XM. Identification and validation co-differentially expressed genes with NAFLD and insulin resistance. Endocrine. 2015; 48(1):143-51. doi: 10.1007/s12020-014-0247-5 PMID: 24699882
29. Patel SA, Hoehn KL, Lawrence RT, Sawbridge L, Talbot NA, Tomsig JL, et al. Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity. Endocrinology. 2012; 153(11):5231-46. doi: 10.1210/en.2012-1368 PMID: 22989629
30. Provenzano A, Milani S, Vizzutti F, Delogu W, Navari N, Novo E, et al. n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. Liver Int. 2014; 34 (6):918-30. doi: 10.1111/liv.12500 PMID: 24628836
31. Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol. 2013; 6(4):249-59. doi: 10.1177/1756283X13484078 PMID: 23814606
32. Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012; 15(5):468-73. doi: 10.1097/MCO. 0b013e3283566614 PMID: 22878240
33. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22):2297-307. doi: 10.1056/nejmoa060326 PMID: 17135584
34. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4):1176-84. doi: 10.1053/j.gastro.2008.06.047 PMID: 18718471
35. Saryusz-Wolska M, Szymanska-Garbacz E, Jablkowski M, Bialkowska J, Pawlowski M, Kwiecinska E, et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn. 2011; 121(3):61-6. PMID: 21430606
36. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet (London, England). 2001; 358(9285):893-4. doi: 10.1016/s0140-6736(01)06042-1
37. Foroughi M, Maghsoudi Z, Askari G. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian journal of nursing and midwifery research. 2016; 21(1):100-4. doi: 10.4103/1735-9066.174759 PMID: 26985230
38. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98 (11):2485-90. doi: 10.1111/j.1572-0241.2003.08699.x PMID: 14638353
39. Kawanaka M, Nishino K, Nakamura J, Suehiro M, Goto D, Urata N, et al. Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study. Hepat Med. 2013; 5:11-6. doi: 10.2147/HMER. S41258 PMID: 24695939
40. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012; 10(12):1342-59.e2. doi: 10.1016/j.cgh.2012.10.001 PMID: 23041539
41. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015; 62(6):1723-30. doi: 10.1002/hep.28123 PMID: 26274335
42. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011; 96(4):350-3 doi: 10.1136/adc.2010.192401 PMID: 21233083
43. Nobili V, Bedogni G, Donati B, Alisi A, Valenti L. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food. 2013; 16 (10):957-60 doi: 10.1089/jmf.2013.0043 PMID: 24074360
44. Nobili V, Alisi A, Della Corte C, Rise P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013; 23 (11):1066-70 doi: 10.1016/j.numecd.2012.10.010 PMID: 23220074
45. Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. J Pediatr. 2015; 166(6):1358-63.e1-3 doi: 10.1016/j.jpeds.2015.01.056 PMID: 25771388
46. Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis. 2016; 246:208-13. doi: 10.1016/j.atherosclerosis.2016.01.016 PMID: 26803429
47. Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2015.
48. Marchioli R. [Omega-3 polyunsaturated fatty acids and cardiovascular diseases]. Minerva Cardioangiol. 2003; 51(5):561-76. PMID: 14551524
49. Suzuki-Kemuriyama N, Matsuzaka T, Kuba M, Ohno H, Han SI, Takeuchi Y, et al. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. PLoS One. 2016; 11(6):e0157580. doi: 10.1371/journal.pone.0157580 PMID: 27333187
50. Jump DB, Depner CM, Tripathy S, Lytle KA. Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutr. 2015; 6(6):694-702. doi: 10.3945/an.115.009423 PMID: 26567194
51. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol. 2004; 23(4):131-4. PMID: 15333967
52. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008; 42(4):413-8. doi: 10. 1097/MCG.0b013e31815591aa PMID: 18277895
53. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006; 23(8):1143-51. doi: 10.1111/j.1365-2036.2006. 02885.x PMID: 16611275
54. Provenzano A, Milani S, Vizzutti F, Delogu W, Navari N, Novo E, et al. n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. Liver Int. 2014; 34 (6):918-30. doi: 10.1111/liv.12500 PMID: 24628836
55. Cormier H, Rudkowska I, Lemieux S, Couture P, Vohl MC. Expression and Sequence Variants of Inflammatory Genes; Effects on Plasma Inflammation Biomarkers Following a 6-Week Supplementation with Fish Oil. Int J Mol Sci. 2016; 17(3). doi: 10.3390/ijms17030375 PMID: 26999109
56. Lalia AZ, Johnson ML, Jensen MD, Hames KC, Port JD, Lanza IR. Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans. Diabetes Care. 2015; 38 (7):1228-37. doi: 10.2337/dc14-3101 PMID: 25852206